<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04285359</url>
  </required_header>
  <id_info>
    <org_study_id>PPN-2020-02-06</org_study_id>
    <nct_id>NCT04285359</nct_id>
  </id_info>
  <brief_title>Impact of Severe Intraoperative Hyperglycemia on Infection Rate After Elective Intracranial Interventions</brief_title>
  <official_title>Impact of Severe Intraoperative Hyperglycemia on Infection Rate After Elective Intracranial Interventions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Burdenko Neurosurgery Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Burdenko Neurosurgery Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe intraoperative hyperglycemia (SIH) is recognized as one of the important risk factors
      for the increasing of the postoperative infections rate, which can negatively affect the
      final outcome of surgical treatment. Studies in recent years have shown a much higher
      incidence of wound infections, respiratory and urinary tract infections in patients who
      intraoperatively had an increase in blood glucose level (BGL) above 180 mg/dl (10 mmol/l).
      This problem in neurosurgery is especially important due to the high proportion of patients
      with acute injuries and potentially long-term need for postoperative intensive care, as well
      as the frequent use of drugs that increase blood glucose level (steroids) in neurooncology.
      Most published studies include patients from both of these groups. This study is aimed to
      assess the impact of severe intraoperative hyperglycemia on the incidence of infectious
      complications only in patients scheduled for elective intracranial interventions.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Infection rate</measure>
    <time_frame>7 days after surgery</time_frame>
    <description>Proportion of patients diagnosed with infection (wound, pulmonary, urological, blood etc.) in the postoperative period according to CDC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibiotic prophylaxis</measure>
    <time_frame>Preoperatively</time_frame>
    <description>Antibiotic usage for prevention of postop infection: type and dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose level</measure>
    <time_frame>Twice intraoperatively: before incision and at the end of surgery</time_frame>
    <description>Intraoperative glucose level in whole blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>History of steroids usage</measure>
    <time_frame>Preoperatively</time_frame>
    <description>Dosages and regimen of dexamethasone in the perioperative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin dosage</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>Intraoperative dose of insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>Perioperative complications (episodes of hemodynamic instability, blood loss, etc.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stay in ICU and hospital</measure>
    <time_frame>30 days</time_frame>
    <description>Length of stay in ICU (in hours) and in hospital (in days) after surgical intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment outcome</measure>
    <time_frame>30 days</time_frame>
    <description>Outcome at the moment of discharge (improved,unchanged, worsened, death)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hyperglycemia</condition>
  <condition>Craniotomy</condition>
  <condition>Infection Post Op</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intracranial Interventions</intervention_name>
    <description>Neurosurgical elective intracranial interventions: supra- and infratentorial craniotomies, transnasal endoscopic interventions.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients (&gt;18 years) scheduled for elective intracranial intervention.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adult patients (&gt;18 years) scheduled for elective intracranial (open or endoscopic)
        intervention.

        Exclusion Criteria:

        Diagnosis of infection (local or systemic) in preoperative period; urgent intervention.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Kulikov</last_name>
    <role>Principal Investigator</role>
    <affiliation>Burdenko National Medical Research Center of Neurosurgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Kulikov</last_name>
    <phone>+79039637364</phone>
    <email>akulikov@nsi.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sapienza University of Rome</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Federico Bilotta</last_name>
      <email>bilotta@tiscali.it</email>
    </contact>
    <investigator>
      <last_name>Ega Qeva</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal State Autonomous Institution &quot;N .N. Burdenko National Medical Research Center of Neurosurgery&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>125047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexander Kulikov</last_name>
      <phone>+79039637364</phone>
      <email>akulikov@nsi.ru</email>
    </contact>
    <investigator>
      <last_name>Alexander Shmigelsky</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Nikitin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 22, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

